Evidence map›Paper›PMID 40185990›Full record

ArticleScientific reports2025

Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study.

Douglas D Fraser, Devika Singh, Enis Cela, Maitray A Patel, Maysaa Assaf, Maritza Quintero, Michael Knauer, Michael R Miller, Melina Bellini, Angela Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Douglas D FraserPediatrics, Western University, London, ON, Canada. douglas.fraser@lhsc.on.ca.
Devika SinghPediatrics, Western University, London, ON, Canada.
Enis CelaPhysiology and Pharmacology, Western University, London, ON, Canada.
Maitray A PatelEpidemiology and Biostatistics, Western University, London, ON, Canada.
Maysaa AssafPediatrics, Western University, London, ON, Canada.
Maritza QuinteroPediatrics, Western University, London, ON, Canada.
Michael KnauerPathology and Laboratory Medicine, Western University, London, ON, Canada.
Michael R MillerPediatrics, Western University, London, ON, Canada.
Melina BelliniDiagnostics Biochem Canada Inc, London, ON, Canada.
Angela LiDiagnostics Biochem Canada Inc, London, ON, Canada.
Paul HahnDiagnostics Biochem Canada Inc, London, ON, Canada.
Marta HrekDiagnostics Biochem Canada Inc, London, ON, Canada.
Jorge Cruz-AguadoDiagnostics Biochem Canada Inc, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge regarding the pediatric immune response to SARS-CoV-2 infection and/or vaccination remains limited, particularly for the variants of concern (VOC). Our objective was to evaluate the neutralizing antibody response against SARS-CoV-2 VOC in the naturally infected and/or vaccinated pediatric population. Participants aged 5-12 years who presented to either an outpatient clinic or emergency room were eligible for participation in this study. Participants were divided into four groups based on infection and vaccination status. Plasma was tested using immunoassays targeting anti-SARS-CoV-2 IgG, spike protein, and nucleocapsid. A total of 619 participants met study inclusion. Natural infection was identified in 189/619 children (31%), 284/619 were vaccinated (46%) and 69/619 were both naturally infected and vaccinated (11%). Participants that were vaccinated had received one (n = 169/619; 27%) or two (n = 115/619; 19%) vaccine doses. The median time between the 1st and 2nd vaccine doses was 56 days, interquartile range 50-56. A general upward trend in antibody positivity was observed across all VOC as the study proceeded over a 5-month period. Omicron antibody responses were lower than those of other VOC, both in relation to the percentage of positive cases and over time. Neither asthma nor diabetes altered antibody responses, but antibody titres were reduced for a variety of VOC in those children receiving immunotherapy or with leukopenia. This study demonstrated decreased neutralizing antibody responses against the Omicron variant, regardless of past infection or vaccination status. These findings emphasize the need for continued neutralizing antibody surveillance.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2ChildChild, PreschoolCOVID-19 VaccinesFemaleHumansImmunoglobulin GMaleSpike Glycoprotein, CoronavirusVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID40185990
PMCPMC11971435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.